{
    "organizations": [],
    "uuid": "cd2845118fabee47ebb38fa7086e9147204c6c83",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/02/globe-newswire-neos-therapeutics-to-host-first-quarter-2018-financial-results-conference-call-on-may-9-2018.html",
    "ord_in_thread": 0,
    "title": "Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "DALLAS and FORT WORTH, Texas, Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that it will report first quarter 2018 financial results prior to the opening of U.S. financial markets on Wednesday, May 9, 2018. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.\nThe live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 1988619. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ .\nAbout Neos Therapeutics\nNeos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT ® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), Cotempla XR-ODT ® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), and Adzenys ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information , including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com .\nContacts:\nRichard Eisenstadt\nChief Financial Officer\nNeos Therapeutics\n(972) 408-1389\nreisenstadt@neostx.com\nSarah McCabe\nSenior Vice President\nStern Investor Relations, Inc.\n(212) 362-1200\nsarah@sternir.com\nSource:Neos Therapeutics, Inc.",
    "published": "2018-05-02T15:30:00.000+03:00",
    "crawled": "2018-05-02T15:53:40.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "dallas",
        "fort",
        "worth",
        "texas",
        "neos",
        "therapeutic",
        "nasdaq",
        "neos",
        "pharmaceutical",
        "company",
        "focused",
        "developing",
        "manufacturing",
        "commercializing",
        "innovative",
        "xr",
        "product",
        "using",
        "proprietary",
        "drug",
        "delivery",
        "technology",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "prior",
        "opening",
        "financial",
        "market",
        "wednesday",
        "may",
        "neos",
        "management",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "discus",
        "result",
        "provide",
        "company",
        "update",
        "et",
        "day",
        "live",
        "call",
        "may",
        "accessed",
        "dialing",
        "domestic",
        "call",
        "international",
        "caller",
        "referencing",
        "conference",
        "id",
        "number",
        "live",
        "audio",
        "webcast",
        "conference",
        "call",
        "available",
        "investor",
        "relation",
        "page",
        "company",
        "website",
        "http",
        "neos",
        "therapeutic",
        "neos",
        "therapeutic",
        "nasdaq",
        "neos",
        "pharmaceutical",
        "company",
        "focused",
        "developing",
        "manufacturing",
        "commercializing",
        "product",
        "utilizing",
        "proprietary",
        "drug",
        "delivery",
        "technology",
        "platform",
        "adzenys",
        "amphetamine",
        "orally",
        "disintegrating",
        "tablet",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "cotempla",
        "methylphenidate",
        "orally",
        "disintegrating",
        "tablet",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "adzenys",
        "amphetamine",
        "oral",
        "suspension",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "treatment",
        "adhd",
        "first",
        "three",
        "approved",
        "product",
        "using",
        "company",
        "technology",
        "platform",
        "additional",
        "information",
        "neos",
        "available",
        "contact",
        "richard",
        "eisenstadt",
        "chief",
        "financial",
        "officer",
        "neos",
        "therapeutic",
        "reisenstadt",
        "sarah",
        "mccabe",
        "senior",
        "vice",
        "president",
        "stern",
        "investor",
        "relation",
        "sarah",
        "source",
        "neos",
        "therapeutic",
        "inc"
    ]
}